1. Acetylcorynoline has anti-inflammatory properties, it also has potential to improve parkinson's disease, it may exert its effects by decreasing egl-1 expression to suppress apoptosis pathways and by increasing rpn5 expression to enhance the activity of proteasomes.
2. Acetylcorynoline may be one of the potent immunosuppressive agents through the blockage of dendritic cells maturation and function.
3. Acetylcorynoline has protective action against experimental liver injury in mice.
1. Irisflorentin has anti-inflammatory activity in lipopolysaccharides (LPS)-stimulated RAW 264.7 macrophages, it can markedly reduce the transcriptional and translational levels of inducible nitric oxide synthase (iNOS) as well as the production of NO, it also can significantly inhibit TNF-α, IL-1βand IL-6 at both the transcriptional and translational levels.
2. Irisflorentin has potential to ameliorate Parkinson’s disease in Caenorhabditis elegans models, it may exert its effects by promoting rpn-3 expression to enhance the activity of proteasomes and down-regulating egl-1 expression to block apoptosis pathways.
3. Irisflorentin modifies properties of mouse bone marrow-derived dendritic cells and reduces the allergic contact hypersensitivity responses, suggests that irisflorentin may as an immunotherapeutic adjuvant.
1. Levodopa and HSYA reduced the likelihood of wearing off development, and may thus support the utility of such compounds for the improved treatment of PD.
2. Levodopa's toxic effects masks the potential ability of HP-β-CD via complexation.
1. Schisantherin A exhibits anti-inflammatory and antioxidant effects, it can significantly attenuate Aβ1-42-induced learning and memory impairment and noticeably improve the histopathological changes in the hippocampus, it could serve as a potential agent in treatment of Alzheimer's disease.
2. Schisantherin A can protect against myocardial ischemia-reperfusion injury, the underlining mechanism may be related to its role in inhibiting cardiomyocyte apoptosis.
3. Schisantherin A shows anti-inflammatory potentials, it may inhibit LPS-induced production of inflammatory cytokines by blocking NF-kappaB and MAPKs signaling in RAW264.7 cells.
4. 100 muM of Deoxyschizandrin and schisantherin A exhibit strong inhibition on UDP-glucuronosyltransferases (UGTs)1A3, suggests that herb-drug interaction may occur when deoxyschizandrin or schisantherin A containing herbs were co-administered with drugs which mainly undergo UGT1A3-mediated metabolism.
5. Schisantherin A has been used as an antitussive, tonic, and sedative agent, it also can attenuate osteoclast formation and wear particle-induced osteolysis by mediating RANKL signaling pathways, indicates that it is a promising therapeutic natural compound for the treatment of osteoclast-related prosthesis loosening.
6. Schisantherin A exhibits neuroprotection against 1-methyl-4-phenylpyridinium ion (MPP(+)) through the regulation of two distinct pathways including increasing CREB-mediated Bcl-2 expression and activating PI3K/Akt survival signaling, suggests that it may be a promising neuroprotective agent for the prevention of Parkinson's disease.
1. Rasagiline mesylate (TVP-1012) is a potent, selective, non-reversible MAO-B inhibitor, without the tyramine-potentiating effect and with neuroprotective activities, with anti-Parkinson activity.
2. Rasagiline mesylate exhibits neuroprotective and anti-apoptotic activity against several neurotoxins in cell culture.